The active substance designated Chlordiazepoxide Veterinary Grade API, manufacturer model CDZ-VET-API-2207, is the benzodiazepine derivative 7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide base, CAS 58-25-3, supplied as a white to pale yellow crystalline powder for downstream incorporation into tablets, capsules, injectable solutions, oral powders, granules, medicated premix blends, and liquid solutions. The free base is used for solid oral dosage forms, while the hydrochloride salt is required for aqueous parenteral preparations because the base exhibits aqueous solubility below 0.1 mg/mL at 25 °C. The veterinary grade designation does not identify a separate chemical entity: no dedicated veterinary monograph for chlordiazepoxide is currently published in Ph. Eur., and the material is released against the active substance monograph for chlordiazepoxide with additional manufacturer certificates that support veterinary good manufacturing practice and multi-species feed applications. The product is supplied only to licensed pharmaceutical manufacturers and compounding facilities; national controlled substance regulations apply because chlordiazepoxide is a Schedule IV controlled substance in the United States under 21 CFR 1308.14 and equivalent schedules in other jurisdictions.

Compendial Specifications and Vendor Certification Pathways

Specification alignment is based on the current Ph. Eur. and USP monographs for chlordiazepoxide. The API is not released solely on assay; the certificate of analysis includes identification by infrared absorption, related substances by liquid chromatography, loss on drying, residual solvents, and elemental impurities. Assay is controlled at 99.0–101.0% on the dried basis, loss on drying at ≤0.5%, and unspecified individual related substances at ≤0.10%. Residual solvent reporting follows ICH Q3C with Ph. Eur. 5.4; Class 1 solvents benzene, carbon tetrachloride, 1,2-dichloroethane, and 1,1-dichloroethene are controlled to regulatory limits, with benzene at 2 ppm, carbon tetrachloride at 4 ppm, 1,2-dichloroethane at 5 ppm, and 1,1-dichloroethene at 8 ppm. Elemental impurity control uses ICH Q3D and Ph. Eur. 5.20; for oral dosage forms, the lead permitted daily exposure of 5 µg/day is used to calculate the drug-product limit from the maximum daily API intake.

Material intended for direct compression is milled to a particle size distribution with D90 ≤ 180 µm and D10 ≥ 20 µm to reduce segregation during rotary tablet press operation. Batches with a wide span above 2.5 are at increased risk of content uniformity drift in low-dose tablets when the paddle feeder speed exceeds 30 rpm on a 16-station rotary press. The corrective action is to pre-blend 0.5–1.0% w/w colloidal silicon dioxide and to maintain hopper fill above 40%. Finished product uniformity of dosage units must meet an acceptance value ≤15 under Ph. Eur. 2.9.40 and USP 905.

Why Does the Free Base Restrict Injectable Formulation Development?

Injectable formulations use chlordiazepoxide hydrochloride, not the free base. The free base has insufficient water solubility to meet a 5 mg/mL parenteral concentration and precipitates when pH is adjusted toward the physiological range. The hydrochloride salt is dissolved in water for injection, and the solution is maintained at pH 2.5–3.5; degradation increases above pH 4.0, and alkaline conditions accelerate benzodiazepine lactam ring opening. Terminal sterilisation is performed at 121 °C for 15 min only in validated borosilicate or neutral glass vials with halobutyl rubber stoppers; where terminal sterilisation is not possible, aseptic filtration through 0.22 µm polyethersulfone filters is applied. The choice between terminal sterilisation and aseptic processing must be documented in the finished-product dossier, because the API supplier cannot guarantee sterility of the non-sterile powder grade.

Dry blending for medicated premix and granule applications is carried out in ribbon blenders with working capacities from 200 L to 1000 L. A two-stage dilution procedure is used: the API is first pre-blended with carrier at a 1:10 ratio for 10 min, then added to the full batch and mixed for 20–30 min to achieve blend uniformity relative standard deviation below 5.0%. Carriers are selected to match API particle size and density; lactose monohydrate with D50 100–150 µm is common for granule premix, while calcium carbonate is restricted to formulations where lactose is excluded. Moisture-sensitive powder sachets are filled under ≤40% RH and heat-sealed in aluminium foil laminate with moisture vapour transmission rate below 0.5 g/m²/day at 38 °C and 90% RH.

When wet granulation is required, a high-shear mixer-granulator with a 65 L bowl and chopper speed 1500 rpm is used to disperse the API in a starch paste; the wet mass is dried in a fluid-bed dryer with inlet air temperature 50–75 °C and product temperature monitored below 45 °C to avoid degradation. Granule moisture is controlled at 1.0–2.5% before compression; moisture above 3.0% increases picking and sticking on punch faces, while moisture below 0.5% increases friability and lamination risk.

When a Premix Manufacturer Switches from Human-Grade to Veterinary-Grade API

The chemical entity is identical, but the documentation and particle size profiles differ from human-grade chlordiazepoxide API. A veterinary-grade batch release includes a BSE/TSE declaration for raw materials of animal origin, a statement of compliance with the veterinary medicinal product provisions of Regulation EU 2019/6 where applicable, and evidence that the manufacturing line is segregated from ionophores and other agents toxic to target species. Human-grade certificates of analysis rarely include these veterinary-specific declarations. In addition, veterinary premix grades are often supplied at D90 ≤ 250 µm, whereas human tablet-grade API at D90 ≤ 180 µm may produce over-blending and segregation in feed-mill equipment with high-shear paddles; this physical difference is sufficient to invalidate a formulation change without new blend uniformity data.

For capsule filling, the API is pre-screened through a 0.710 mm mesh and blended with lactose monohydrate and magnesium stearate. Dosator-type capsule machines show consistent weight variation below 3% when the powder bed density remains between 0.55 g/cm³ and 0.65 g/cm³; low-density powder with high air entrapment causes capsule plug weight drift. The blend is compressed into slugs on a rotary tablet press at 8–12 kN for slugging or processed by roller compaction with ribbon density controlled at 1.05–1.15 g/cm³.

Oral liquid preparations are compounded from the hydrochloride salt rather than the base. The working pH is held below 4.0 to maintain chemical stability, and buffered vehicles prepared with citrate or phosphate systems are not interchangeable without forced degradation testing because benzodiazepine lactam ring opening is pH- and buffer-dependent. Stainless steel jacketed vessels with bottom-mounted agitators are used at 200–500 rpm; nitrogen sparging is applied when oxygen-sensitive flavouring systems are used. Published long-term stability data for chlordiazepoxide veterinary oral solutions above pH 5.0 is limited, so manufacturers cannot substitute diazepam solution data without confirming the degradation product profile under the intended storage condition.

Comparative pharmacokinetic data in dogs indicate that chlordiazepoxide is not milligram-equivalent to diazepam; published reports describe a longer terminal half-life for chlordiazepoxide, but published data for this specific veterinary-grade configuration is limited. Formulators cannot use diazepam injectable stability data to qualify chlordiazepoxide hydrochloride solutions because the degradation product profile and pH-rate dependence differ.

Residual Solvent and Elemental Impurity Compliance for Multi-Species Premix Use

Residual solvent control is critical when the API is incorporated into medicated feed for food-producing species, because solvent exposure from feed must be accounted for in withdrawal period and residue evaluations. The supplier reports residual solvent concentrations on each batch and limits Class 2 solvents according to ICH Q3C. The API is released only when benzene is below 2 ppm, carbon tetrachloride below 4 ppm, 1,2-dichloroethane below 5 ppm, and 1,1-dichloroethene below 8 ppm; the absence of these Class 1 solvents is verified by headspace gas chromatography with flame ionisation detection. Elemental impurities are validated by ICP-MS per Ph. Eur. 5.20; the oral lead limit is calculated from the permitted daily exposure of 5 µg/day. For premix applications, the drug-product lead limit is derived by dividing the permitted daily exposure by the maximum daily feed intake and the target animal body weight, rather than applying a fixed ppm value to the feed matrix.

Packaging for the API is selected to protect the crystalline form and avoid hydrolysis. The product is double-bagged in low-density polyethylene inside aluminium foil laminate with a desiccant sachet, and labelled storage is 15–25 °C in a dry area. Under these conditions, the assigned retest interval is 24 months when the container remains unopened; opened containers are retested for water content because chlordiazepoxide hydrochloride can absorb atmospheric moisture and shift the assay on the dried basis.